The Future of Biopharma: China and Saudi Arabia are redefining "Pharmerging"

Viewpoints

The Future of Biopharma: China and Saudi Arabia are redefining “Pharmerging”

Read time: 7 mins

The traditional binary definitions of “Developed” markets (the 10 largest countries with high incomes and pharmaceutical spending >$10Bn)^[1] versus “Pharmerging” markets (countries with GDP <$30,000/year and >$1Bn growth)^[1] are blurring. The future of the biopharma industry is increasingly centered on economies that were once considered peripheral but are now central to global growth.

Consumption Parity: Pharmaceutical consumption in key markets has shifted. Saudi Arabia’s per capita consumption (defined daily doses) is now comparable to developed markets like Australia ^[2]. Similarly, China tops regions for expected per capita growth with 1.8% CAGR to 2029, even as volume growth stabilizes ^[3].
The Divergence: While the “pharmerging” bloc will drive volume (reaching 3.8 trillion doses globally by 2029), China and Saudi Arabia have diverged from the pack. They are no longer just driving volume; they are driving value. Saudi Arabia has solidified its status as the largest market in the MENA region (valued at $11.6 billion) ^[4], while China has cemented itself as the world’s second-largest market ^[5].

The “Developed Market” Litmus Test:

If we hold China and Saudi Arabia against the criteria used to define a “Developed Pharmaceutical Market,” they now check the critical boxes that define maturity.

Criteria	Developed Standard	China’s Status	Saudi Arabia’s Status
R&D Base	Strong focus on innovation and new therapies.	Established. #2 globally in R&D output; 48 first-in-class drugs approved in a single year.	Evolving. Transitioning to discovery via partnerships (e.g., Flagship Pioneering).
Regulatory Framework	Rigorous standards (FDA/EMA equivalence).	Established. Review times cut from ~5 years to <2 years.	Established. SFDA expedited pathways as fast as 30 days.
MNC Presence	Strategic regional hubs.	Anchored. Global first-launch market for Roche & AstraZeneca.	Anchored. Manufacturing hubs for Sanofi & Novo Nordisk.
Spending Power	High per capita expenditure.	Growing. Commercial insurance bridging the gap for high-value care.	High. Full reimbursement for citizens; high-value deals.

3. The China Market Explosion: A Global Innovation Hub China has transitioned from a “volume-based” market to a “value-based” innovation engine filling the global innovation gap.

Regulatory Record-Breaking: The National Medical Products Administration (NMPA) approved 83 new drugs in 2024, a 12% increase year-on-year ^[6]. This surge is not generic; it includes cutting-edge therapies in oncology and immunology.
Exporting Innovation: China is no longer just importing Western drugs; it is exporting its own. In 2024, 28% of all global out-licensing deals originated from Chinese biotechs, with deal values hitting $41.5 billion ^[7]. Major multinationals are now reliant on Chinese labs to replenish their pipelines.“We see China playing at the same level of scientific capabilities, rigor, and innovation as Boston, Berlin, and Kobe.” — Stefan Oelrich, Bayer
Funding the Future: With public insurance (VBP) managing basic care, commercial health insurance has stepped in to fund innovation, growing at ~8.8% to cover high-cost specialty medicines ^[8].

4. Saudi Arabia: Vision 2030 and Industrial Execution Saudi Arabia has moved from “Vision” to “Execution,” leveraging state policy to mandate the localization of the pharmaceutical industry.

Policy Support: Vision 2030 has successfully created a “Pay-to-Play” environment. The government has linked market access to industrial commitment, using its purchasing power to mandate local manufacturing.
Future Initiatives (2025 Updates): At the Global Health Exhibition (GHE) in Riyadh, a record $35.5 billion in healthcare agreements were signed, signaling a decisive shift toward local industrialization ^[9]. The event was headlined by landmark manufacturing deals, including Novo Nordisk’s agreement to localize GLP-1 production (Ozempic/Wegovy) and Sanofi’s partnership to localize vaccine production ^[10].“Local insulin production is ensuring world-class treatment is available where it’s needed—by Saudis, for Saudi, in Saudi.” — Sanofi Corporate Statement
Clinical Pivot: In November 2025, the Kingdom moved into discovery through a $70 million partnership between Flagship Pioneering and KAIMRC, signaling its intent to become a clinical trial hub ^[11].

5. Developing Access to Medicine Through Policy Both nations are rewriting the rulebook on how patients access these innovations.

In China (The NRDL Evolution): Access is defined by the National Reimbursement Drug List (NRDL). The speed of inclusion has accelerated—80% of new drugs are listed within two years of launch.
In Saudi Arabia (Localization as Access): Access is now defined by Localization. The “NUPCO tenders,” the primary vehicle for government procurement, are increasingly ring-fenced for companies with local manufacturing. The policy is clear: build locally to ensure patient access globally within the Kingdom.

6. The Strategic Pivot: The “10 As” Framework To succeed in these transformed markets, the traditional “4 Ps” (Product, Price, Place, Promotion) are obsolete. We must adopt the “10 As” to navigate the non-market barriers that now determine success:

Awareness: Educating stakeholders on disease burden.
Acceptance: Gaining buy-in from key opinion leaders (KOLs) and HTA bodies.
Accessibility: Ensuring physical reach (overcoming China’s tiered hospital system).
Availability: Securing regulatory approval (leveraging Saudi’s 30-day expedited review).
Affordability: Navigating reimbursement cliffs.
Adherence: Supporting patient compliance programs.
Appropriate Use: Ensuring correct prescription in complex therapy areas.
Adaptation: Tailoring pack sizes and formulations to local preferences.
Ancillary Support: Providing patient support programs (PSPs).
Actors (Alignment): The most critical “A” for 2026, aligning with state actors like the PIF in Saudi Arabia or the NHSA in China.